Xtant Medical Holdings, Inc. 8-K

What Happened

• Xtant Medical Holdings, Inc. announced on April 13, 2026 (8-K filed) that it entered into a Distribution Agreement with Dilon Technologies, Inc. to obtain exclusive rights to import, market, distribute and sell the FDA‑approved HEMOBLAST® Bellows topical surgical hemostatic product in the United States. The Distribution Agreement was signed on April 10, 2026.

Key Details

• Xtant paid Dilon a $5.0 million exclusivity fee; the fee is subject to repayment by Dilon under certain conditions, including upon termination of the agreement.
• Dilon will continue manufacturing the product at its current facility in France and will supply Xtant at a transfer price set in the agreement (price subject to change per the contract).
• The agreement imposes no minimum purchase requirements on Xtant.
• Xtant hired approximately 20 former Dilon sales personnel to support U.S. sales and Dilon agreed to cooperate in transitioning existing U.S. customer contracts to Xtant (subject to Xtant’s review/approval).

Why It Matters

• The deal gives Xtant exclusive U.S. distribution of an FDA‑approved surgical hemostat, expanding its product portfolio and direct exposure to the surgical hemostasis market.
• Investors should note the $5.0M upfront exclusivity payment and the absence of minimum purchase obligations — meaning Xtant has exclusivity but also bears commercial risk if sales are slower than expected.
• Continued manufacturing by Dilon and the immediate addition of ~20 sales reps suggest Xtant can begin selling the product quickly, but supply, transfer pricing and contract transitions will influence margins and timing of revenue.